Literature DB >> 31719907

Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD.

Katy C Norman1, Christine M Freeman2,3,4, Neha S Bidthanapally1, MeiLan K Han2, Fernando J Martinez5, Jeffrey L Curtis2,4,6, Kelly B Arnold1.   

Abstract

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States, with high associated costs. Most of the cost burden results from acute exacerbations of COPD (AE-COPD), events associated with heightened symptoms and mortality. Cellular mechanisms underlying AE-COPD are poorly understood, likely because they arise from dysregulation of complex immune networks across multiple tissue compartments.
METHODS: To gain systems-level insight into cellular environments relevant to exacerbation, we applied data-driven modeling approaches to measurements of immune factors (cytokines and flow cytometry) measured previously in two different human tissue environments (sputum and peripheral blood) during the stable and exacerbated state.
RESULTS: Using partial least squares discriminant analysis, we identified a unique signature of cytokines in serum that differentiated stable and AE-COPD better than individual measurements. Furthermore, we found that models integrating data across tissue compartments (serum and sputum) trended towards being more accurate. The resulting paracrine signature defining AE-COPD events combined elevations of proteins associated with cell adhesion (sVCAM-1, sICAM-1) and increased levels of neutrophils and dendritic cells in blood with elevated chemoattractants (IP-10 and MCP-2) in sputum.
CONCLUSIONS: Our results supported a new hypothesis that AE-COPD is driven by immune cell trafficking into the lung, which requires expression of cell adhesion molecules and raised levels of innate immune cells in blood, with parallel upregulated expression of specific chemokines in pulmonary tissue. Overall, this work serves as a proof-of-concept for using data-driven modeling approaches to generate new insights into cellular processes involved in complex pulmonary diseases. © Biomedical Engineering Society 2019.

Entities:  

Keywords:  Data-driven models; Immune system; Inflammation; Pulmonary disease; Systems biology

Year:  2019        PMID: 31719907      PMCID: PMC6816611          DOI: 10.1007/s12195-019-00567-2

Source DB:  PubMed          Journal:  Cell Mol Bioeng        ISSN: 1865-5025            Impact factor:   2.321


  57 in total

Review 1.  Immunologic aspects of chronic obstructive pulmonary disease.

Authors:  Manuel G Cosio; Marina Saetta; Alvar Agusti
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

2.  Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils.

Authors:  Subhadeep Chakrabarti; Kamala D Patel
Journal:  J Leukoc Biol       Date:  2005-04-14       Impact factor: 4.962

3.  Glucocorticoids relieve collectin-driven suppression of apoptotic cell uptake in murine alveolar macrophages through downregulation of SIRPα.

Authors:  Alexandra L McCubbrey; Joanne Sonstein; Theresa M Ames; Christine M Freeman; Jeffrey L Curtis
Journal:  J Immunol       Date:  2012-05-21       Impact factor: 5.422

4.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Authors:  Jadwiga A Wedzicha; Donald Banerji; Kenneth R Chapman; Jørgen Vestbo; Nicolas Roche; R Timothy Ayers; Chau Thach; Robert Fogel; Francesco Patalano; Claus F Vogelmeier
Journal:  N Engl J Med       Date:  2016-05-15       Impact factor: 91.245

5.  Predictors of outcomes in COPD exacerbation cases presenting to the emergency department.

Authors:  N Roche; M Zureik; D Soussan; F Neukirch; D Perrotin
Journal:  Eur Respir J       Date:  2008-05-28       Impact factor: 16.671

6.  Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.

Authors:  Mette Thomsen; Truls Sylvan Ingebrigtsen; Jacob Louis Marott; Morten Dahl; Peter Lange; Jørgen Vestbo; Børge G Nordestgaard
Journal:  JAMA       Date:  2013-06-12       Impact factor: 56.272

Review 7.  Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Yuji Oba; Nazir A Lone
Journal:  Ther Adv Respir Dis       Date:  2012-11-29       Impact factor: 4.031

8.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.

Authors:  Mona Bafadhel; Susan McKenna; Sarah Terry; Vijay Mistry; Carlene Reid; Pranabashis Haldar; Margaret McCormick; Koirobi Haldar; Tatiana Kebadze; Annelyse Duvoix; Kerstin Lindblad; Hemu Patel; Paul Rugman; Paul Dodson; Martin Jenkins; Michael Saunders; Paul Newbold; Ruth H Green; Per Venge; David A Lomas; Michael R Barer; Sebastian L Johnston; Ian D Pavord; Christopher E Brightling
Journal:  Am J Respir Crit Care Med       Date:  2011-09-15       Impact factor: 21.405

9.  Systemic signs of neutrophil mobilization during clinically stable periods and during exacerbations in smokers with obstructive pulmonary disease.

Authors:  Kristina Andelid; Anders Andersson; Shigemi Yoshihara; Christina Åhrén; Pernilla Jirholt; Ann Ekberg-Jansson; Anders Lindén
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-30

10.  The predictive role of serum and bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress syndrome development and outcome.

Authors:  Panagiotis Agouridakis; Despina Kyriakou; Michael G Alexandrakis; Athanasios Prekates; Kostas Perisinakis; Nikolaos Karkavitsas; Demosthenes Bouros
Journal:  Respir Res       Date:  2002-10-23
View more
  1 in total

1.  Identification of a unique temporal signature in blood and BAL associated with IPF progression.

Authors:  Katy C Norman; David N O'Dwyer; Margaret L Salisbury; Katarina M DiLillo; Vibha N Lama; Meng Xia; Stephen J Gurczynski; Eric S White; Kevin R Flaherty; Fernando J Martinez; Susan Murray; Bethany B Moore; Kelly B Arnold
Journal:  Sci Rep       Date:  2020-07-21       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.